Related Experiment Video
Updated: Jun 19, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment
Sheila E Taube1, Gary M Clark, Janet E Dancey
1ST-Consulting, PO Box 260, Glen Echo, MD 20812-0260, USA. taubese63@alumni.brandeis.edu
Journal of the National Cancer Institute
|October 27, 2009
Summary
Biomarker development requires understanding target biology and assay performance. Rigorous scientific approaches and early regulatory interaction streamline drug and biomarker codevelopment for clinical practice.
Area of Science:
- Biomarker discovery and development
- Translational science
- Regulatory science
Background:
- Workshop convened by National Cancer Institute and US Food and Drug Administration to discuss biomarker development challenges.
- Addressed lessons learned and ongoing issues in biomarker and drug codevelopment.
Framework:
- Product development hinges on understanding target biology, drug interactions, and disease processes.
- Stronger biological understanding and validated analytical signals reduce development risks and increase efficiency.
Implementation:
- Emphasized rigorous scientific methods, including meticulous specimen collection and standardized, quality-controlled data acquisition.
- Highlighted the importance of early engagement with regulatory bodies for appropriate study design.
Implications:
- Accelerated clinical adoption of novel diagnostics and therapeutics through optimized development pathways.
- Ensuring robust biomarker assay performance and well-characterized test results for reliable clinical application.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...